Syndax Pharmaceuticals, Inc.
NASDAQ•SNDX
CEO: Mr. Michael A. Metzger M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2016-03-02
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Contact Information
Market Cap
$1.77B
P/E (TTM)
-5.8
40.1
Dividend Yield
--
52W High
$22.73
52W Low
$8.58
52W Range
Rank58Top 85.6%
2.3
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Weak • 2.3 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025
Financial Dashboard
Q3 2025 Data
Revenue
$45.87M+266.97%
4-Quarter Trend
EPS
-$0.70-28.57%
4-Quarter Trend
FCF
-$70.67M+13.39%
4-Quarter Trend
2025 Q3 Earnings Highlights
Key Highlights
Revuforj Product Revenue Nine months 2025 Product revenue reached $80.6M USD, driven by Revuforj launch post November 2024 approval.
Net Loss Reduction Nine months net loss narrowed to $217.4M USD, improving from $224.6M USD loss in prior comparable period.
New FDA Approval Trigger FDA approved Revuforj for R/R AML with NPM1 mutation, triggering $7.0M milestone payment in October 2025.
Cash and Investments Strong Total cash and investments stood at $456.1M USD as of September 30, 2025, supporting ongoing operations.
Risk Factors
High Accumulated Deficit Accumulated deficit reached $1.4B USD as of September 30, 2025; anticipates incurring significant losses next couple years.
High Operating Expenses Total operating expenses were $314.2M USD for nine months, driven by R&D and commercialization costs.
Clinical Trial Uncertainty Successful development remains highly uncertain; costs and timelines for future clinical trials are difficult to estimate accurately.
Competition Exposure Faces intense competition from established firms; market adoption depends on efficacy versus existing therapies like ruxolitinib.
Outlook
Pipeline Data Readouts Advancing multiple trials including EVOLVE-2 and SAVE; expects data readout for colorectal cancer trial in Q1 2026.
Future Funding Strategy Expects to fund future needs via equity offerings, debt financings, and ongoing collaboration revenue streams.
Niktimvo IPF Trial Progress Enrollment ongoing for MAXPIRE trial evaluating axatilimab for IPF; topline data anticipated in second half of 2026.
Peer Comparison
Revenue (TTM)
$111.55M
$109.23M
$93.54M
Gross Margin (Latest Quarter)
100.0%
ATAI100.0%
95.4%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| PRAX | $5.94B | -22.2 | -66.9% | 0.1% |
| WVE | $2.33B | -19.1 | -72.9% | 76.4% |
| SYRE | $1.90B | -16.5 | -31.2% | 0.0% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
81.4%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention
Research & Insights
Next earnings:Mar 2, 2026
EPS:-$0.66
|Revenue:-
Reports
All Years
Form 10-Q - Q3 2025
Period End: Sep 30, 2025|Filed: Nov 3, 2025|Revenue: $45.87M+267.0%|EPS: $-0.70-28.6%MeetForm 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Aug 4, 2025|Revenue: $37.96M+984.5%|EPS: $-0.83+3.8%BeatForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: May 5, 2025|Revenue: $20.04M+0.0%|EPS: $-0.99+16.5%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Mar 3, 2025|Revenue: $23.68M+0.0%|EPS: $-3.73-25.2%MissForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Nov 5, 2024|Revenue: $12.50M+0.0%|EPS: $-0.98+34.2%BeatForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Aug 1, 2024|Revenue: $3.50M+0.0%|EPS: $-0.80+25.0%BeatForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: May 8, 2024|Revenue: $0.00+0.0%|EPS: $-0.85+63.5%N/AForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 27, 2024|Revenue: $0.00+0.0%|EPS: $-2.98-25.7%N/A